Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

NCT06093425 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

820

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal-junction Cancer
Advanced Cancer

Interventions

DRUG: Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil
DRUG: Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil

Sponsor

Suzhou Transcenta Therapeutics Co., Ltd.